Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis

Obstetrics and Gynecology

Volumn 122, Issue 3, 2013, Pages 579-585

  Hawk, Angela F ^a   Chang, Eugene Y ^a   Shields, Sally M ^a   Simpson, Kit N ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIBODY;

ADULT; ALLOIMMUNIZATION; ARTICLE; BLOOD GROUP TYPING; CONTROLLED STUDY; DECISION TREE; FEMALE; HEALTH CARE COST; HOSPITAL BILLING; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; TASK PERFORMANCE;

COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; GENOTYPING TECHNIQUES; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; POSTPARTUM PERIOD; PREGNANCY; RH ISOIMMUNIZATION; RHO(D) IMMUNE GLOBULIN; UNNECESSARY PROCEDURES;

EID: 84883225509     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31829f8814     Document Type: Article

References (23)

1. Wikman AT, Tiblad E, Karlsson A, Olsson M, Westgren M, Reilly M. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012;120: 227-34.
2. Hutchcroft S, Gunton P, Bowen T. Compliance with postpartum Rh isoimmunization prophylaxis in Alberta. CMAJ 1985; 133: 871-5. (Pubitemid 16195493)
3. Hirose TG, Mays DA. The safety of RhIG in the prevention of haemolytic disease of the newborn. J Obstet Gynaecol 2007;27: 545-57. (Pubitemid 47493672)
4. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340: 1228-33. (Pubitemid 29181642)
5. Bombard AT, Akolekar R, Farkas DH, VanAgtmael AL, Aquino F, Oeth P, et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in nonsensitized RhD-negative women. Prenat Diagn 2011;213: 802-8.
6. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350: 485-7. (Pubitemid 27343304)
7. Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Chamberlain PF, et al. Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 1998; 339: 1734-8. (Pubitemid 28555431)
8. Management of alloimmunization during pregnancy. Practice Bulletin No. 75. Obstet Gynecol 2006:108: 457-64.
9. Moise KJ, Boring NH, O'Shaughnessy R, Simpson LL, Wolfe HM, Baxter JK, et al. Circulating cell-free fetal DNA for the detection of RHD status and sex using reflex fetal identifiers. Prenat Diagn 2012;32: 1-6.
10. Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011;11: 1-8.
11. Wijesiriwardana A, Bhattacharya S, Shetty A, Smith N, Bhattacharya S. Obstetric outcome in women with threatened miscarriage in the first trimester. Obstet Gynecol 2006;107: 557-62.
12. Schauberger CW, Mathiason MA, Rooney BL. Ultrasound assessment of first-trimester bleeding. Obstet Gynecol 2005; 105: 333-8. (Pubitemid 40229451)
13. Geifman-Holtzman O, Grotegut CA, Gaughan JP. Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood- a meta-analysis. Am J Obstet Gynecol 2006;195: 1163-73. (Pubitemid 44415679)
14. Akolekar R, Finning K, Kuppusamy R, Daniels G, Nicholaides KH. Fetal RHD genotyping in maternal plasma at 11-13 weeks of gestation. Fetal Diagn Ther 2011;29: 301-6.
15. Klumper FJ, van Kamp IL, Vandenbussche FP, Meerman RH, Oepkes D, et al. Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. Eur J Obstet Gynecol Reprod Biol 2000;92: 91-6.
16. 2010 United States Census Data. Centers for Disease Control and Prevention/NCHS, National Vital Statistics System. Available at: http://www.census.gov/newsroom/cspan/ childbearing/20120817-cspan-childbearing- slides.pdf. Retrieved December 1, 2012.
17. Mari G. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med 2000;342: 9-14. (Pubitemid 30020654)
18. Bowman J. The management of hemolytic disease in the fetus and newborn. Semin Perinatol 1997;21: 39-44. (Pubitemid 27247325)
19. Zipursky A, Paul VK. The global burden of Rh disease. Arch Dis Child Fetal Neonatal Ed 2011;96:F84-5.
20. Moise K. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008;112: 164-76.
21. Murphy K, Topel R. Diminishing returns? The costs and benefits of improving health. Perspect Biol Med 2003;46:S108-28. (Pubitemid 36900725)
22. Minon JM, Gerard C, Senterre JM, Schaaps J-P, Foidart JM. Routine fetal RHD genotyping with maternal plasma: a fouryear experience in Belgium. Transfusion 2008;48: 373-81.
23. Singleton BK, Green CA, Avent ND, Martin PG, Smart E, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the RhD-negative blood group phenotype. Blood 2000;95: 12-8. (Pubitemid 30017219)